BioTuesdays

Tag - H.C. Wainwright

Syros Logo
Markets

HCW ups Syros PT on optimism about AML data at ASH

H.C Wainwright raised its price target for Syros Pharmaceuticals (NASDAQ:SYRS) to $20 from $6, noting that the company’s tamibarotene “looks to shine during ASH ‘22” in December. The stock closed at $3.66 on Nov. 14...

November 15, 2022
Eyenovia Logo
Markets

HCW starts Eyenovia at buy; PT $12

H.C. Wainwright launched coverage of Eyenovia (NASDAQ:EYEN) with a “buy” rating and $12 price target. The stock closed at $2.15 on Oct. 4. Eyenovia is developing ophthalmic therapeutics based on the company’s microdose...

October 5, 2022
Everest Medicines Logo
Markets

HCW starts Everest Medicines at buy; PT $30 HK

H.C. Wainwright launched coverage of Everest Medicines (HKSE:1952.HK) with a “buy” rating and price target of $30 HK. The stock closed at $10.38 HK on Sept. 8. Everest Medicines is an integrated biopharmaceutical...

September 9, 2022
Oyster Point Pharma Logo
Markets

HCW starts Oyster Point Pharma at buy; PT $20

H.C. Wainwright launched coverage of Oyster Point Pharma (NASDAQ:OYST) with a “buy” rating and $20 price target. The stock closed at $4.43 on July 15. Oyster Point Pharma is a commercial stage biopharmaceutical company...

July 18, 2022
Aileron Therapeutics Logo
Markets

HCW cuts Aileron Therapeutics PT to $1 from $2

H.C. Wainwright reduced its price target for Aileron Therapeutics (NASDAQ:ALRN) to $1 from $2, but maintained its “buy” rating, after the company reported “underwhelming” interim data from a Phase 1 study in non-small...

June 30, 2022
Theseus Logo
Markets

HCW starts Theseus Pharma at buy; PT $22

H.C. Wainwright launched coverage of Theseus Pharmaceuticals (NASDAQ:THRX) with a “buy” rating and price target of $22. The stock closed at $5.20 on June 29. “We believe pan-inhibition could be the key to success in...

June 30, 2022
Acumen Pharmaceuticals Logo
Markets

HCW starts Acumen Pharma at buy; PT $15

H.C. Wainwright initiated coverage of Acumen Pharmaceuticals (NASDAQ:ABOS) with a “buy” rating and $15 price target. The stock closed at $4.88 on June 29. Acumen is a clinical-stage biopharmaceutical company developing...

June 30, 2022
Celularity
Markets

HCW starts Celularity at buy; PT $15

H.C. Wainwright initiated coverage of Celularity (NASDAQ:CELU) with a “buy” rating and $15 price target. The stock closed at $3.78 on June 21. Celularity is a clinical-stage biopharmaceutical company focused on...

June 22, 2022
Pulse Biosciences Logo
Markets

HCW cuts Pulse Biosciences to neutral; withdraws PT

H.C. Wainwright downgraded Pulse Biosciences (NASDAQ:PLSE) to “neutral” from “buy” without a price target, reflecting a lack of clarity about Pulse’s commercial timelines and funding availability. The stock closed at $1...

May 13, 2022
Amarin
Markets

Analysts downgrade Amarin; PTs cut to $3

Analysts for H.C. Wainwright and SVB Securities downgraded Amarin (NASDAQ:AMRN) to “neutral” from “ buy” and to “market perform” from “outperform,” respectively. Both analysts cut their prices targets to $3 from $10...

May 5, 2022